Cargando…

The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, TP53 Deletion, and a Poor Prognosis

SIMPLE SUMMARY: Anaplastic large cell lymphoma (ALCL) is a systemic peripheral T-cell neoplasm characterized by strong and uniform CD30 expression and, usually, the aberrant loss of one or more T-cell antigens. ALCL is further classified into anaplastic lymphoma kinase (ALK)-positive and ALK-negativ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiu, Lianqun, Medeiros, L. Jeffrey, Tang, Guilin, Khanlari, Mahsa, Li, Shaoying, Konoplev, Sergej, Wang, Sa A., Yin, C. Cameron, Khoury, Joseph D., Wang, Wei, Miranda, Roberto N., Iyer, Swaminathan, You, M. James, Xu, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699426/ https://www.ncbi.nlm.nih.gov/pubmed/34944936 http://dx.doi.org/10.3390/cancers13246316

Ejemplares similares

DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma
por: Qiu, Lianqun, et al.
Publicado: (2022)

Unique pathologic features and gene expression signatures distinguish blastoid high-grade B-cell lymphoma from B-acute lymphoblastic leukemia/lymphoma
por: Qiu, Lianqun, et al.
Publicado: (2022)

Leukemic phase and CSF involvement of diffuse large B‐cell lymphoma with a complex karyotype including a TP53 deletion
por: Sinkoff, Jillian, et al.
Publicado: (2017)

Blastoid B-Cell Neoplasms: Diagnostic Challenges and Solutions
por: Qiu, Lianqun, et al.
Publicado: (2023)

Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion
por: Hao, Suyang, et al.
Publicado: (2017)

Smudge cells in CD200(+), TP53 mutated leukemic mantle cell lymphoma
por: Jain, Preetesh, et al.
Publicado: (2022)

ALK+ Anaplastic Large Cell Lymphoma of Null Cell Phenotype with Leukemic Transformation and Leukemoid Reaction
por: Chuang, Shih-Sung, et al.
Publicado: (2019)

Leukemic phase as the initial presentation of ALK‐positive anaplastic large‐cell lymphoma complicated by lactic acidosis
por: Nakagawa, Noriharu, et al.
Publicado: (2023)

Biclonal plasma cell leukemia associated with a complex karyotype, TP53 deletion, and high‐risk disease
por: Xie, Wei, et al.
Publicado: (2020)

Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects
por: Tang, Zhenya, et al.
Publicado: (2019)

Immunophenotypic shifts during minimal residual evaluation in a case of leukemic form of anaplastic large cell lymphoma ALK+
por: Canellas, Maria Clara, et al.
Publicado: (2021)

Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
por: Puiggros, Anna, et al.
Publicado: (2017)

Leukemic phase of ALK-negative anaplastic large cell lymphoma in a patient who is on androgenic steroids: A case report
por: Kasinathan, Ganesh
Publicado: (2019)

Anaplastic multiple myeloma resembling dysplastic megakaryocytes
por: Xie, Wei, et al.
Publicado: (2019)

Richter transformation with marked plasmacytic differentiation, mimicking plasma cell neoplasm
por: Li, Shaoying, et al.
Publicado: (2022)

Leukemic manifestation of anaplastic lymphoma kinase-negative-type anaplastic large-cell lymphoma
por: Kim, Jae Wook, et al.
Publicado: (2012)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
por: Subbiah, V., et al.
Publicado: (2021)

Blast phase of chronic myeloid leukemia presenting as early T‐cell precursor lymphoblastic leukemia
por: Qiu, Lianqun, et al.
Publicado: (2021)

Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC
por: Urbán, László, et al.
Publicado: (2020)

Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma
por: Stadler, Serena, et al.
Publicado: (2018)

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
por: Wang, Yuan, et al.
Publicado: (2022)

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
por: Haase, Detlef, et al.
Publicado: (2019)

Pathobiology of ALK-negative anaplastic large cell lymphoma
por: Pileri, Stefano A., et al.
Publicado: (2011)

ALK-positive anaplastic large cell lymphoma in adults
por: Gromowsky, Matthew J, et al.
Publicado: (2023)

An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
por: Turner, Suzanne D.
Publicado: (2017)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)

Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases
por: Fang, Hong, et al.
Publicado: (2022)

MDM4 Overexpressed in Acute Myeloid Leukemia Patients with Complex Karyotype and Wild-Type TP53
por: Li, Li, et al.
Publicado: (2014)

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022)

Unusual Case of Anaplastic Large Cell Lymphoma Presenting as a Breast Mass in a Patient with no History of Breast Implants
por: Ivashkevich, Yana, et al.
Publicado: (2020)

ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma
por: Tabbó, Fabrizio, et al.
Publicado: (2012)

Educational Case: ALK-Negative Anaplastic Large Cell Lymphoma
por: Satou, Akira, et al.
Publicado: (2020)

Deletions of 9p21 and TP53 in bladder cancer.
por: Park, W. S., et al.
Publicado: (1996)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
por: Iwama, Eiji, et al.
Publicado: (2014)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma
por: Lobello, Cosimo, et al.
Publicado: (2020)

Acute leukemic phase of anaplastic lymphoma kinase-anaplastic large cell lymphoma: A case report and review of the literature
por: Zhang, Huai-Feng, et al.
Publicado: (2020)

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
por: Duijkers, Floor A. M., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_rp6ip3j9ipv2ej4o3v6ereedn8